A Phase Ib/II Safety and Efficacy Study of ABC294640 in Patients With Refractory or Relapsed Multiple Myeloma Who Have Previously Been Treated With Proteasome Inhibitors and Immunomodulatory Drugs

Trial Profile

A Phase Ib/II Safety and Efficacy Study of ABC294640 in Patients With Refractory or Relapsed Multiple Myeloma Who Have Previously Been Treated With Proteasome Inhibitors and Immunomodulatory Drugs

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs ABC 294640 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors RedHill Biopharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Dec 2016 According to a RedHill Biopharma media release, the first patient has been screened and dosed in this study.
    • 08 Sep 2016 According to a RedHill Biopharma media release, this study is supported by a $2 million grant from the National Cancer Institute (NCI), awarded to Apogee Biotechnology Corp., with additional support from RedHill
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top